Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Copy of HCV polymerase inhibitor mericitabine boosts interferon/ribavirin cure rate

A 24-week response-guided triple regimen consisting of Roche's NS5B polymerase inhibitor mericitabine plus pegylated interferon and ribavirin produced a greater likelihood of sustained viral suppression than a 48-week course of pegylated interferon/ribavirin alone, according to a report in the January 28, 2013, online advance edition of Hepatology.

Published
13 February 2013
From
HIVandHepatitis.com
FISSION Study Should Support Regulatory Approval For Gilead's Hepatitis C Drug

On Monday, Gilead announced positive top‐line results from two Phase III studies (FISSION and NEUTRINO) that involve the use of sofosbuvir in combination with other agents for use in treatment‐naïve patients infected with the Hepatitis C virus (HCV).

Published
07 February 2013
From
Seeking Alpha
Idenix to Discontinue Development of Two Hepatitis C Treatments

Idenix Pharmaceuticals today announced the Company has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in phase IIb testing for the treatment of hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the Company had previously filed an IND but had not initiated patient dosing.

Published
05 February 2013
From
Idenix press release
Gilead Announces Sustained Virologic Response Rates from Two Phase 3 Studies of Sofosbuvir for Hepatitis C

Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

Published
04 February 2013
From
Gilead press release
Vertex hepatitis C drug revenues plummet

Vertex Pharmaceuticals (Nasdaq: VRTX) saw sales of its hepatitis C drug, Incivek, drop off precipitously in the fourth quarter, year over year. The fast decline in Incivek sales, less than two years after its U.S. Food and Drug Administration approval.

Published
30 January 2013
From
Boston Business Journal (blog)
Hepatitis C progress in pipeline: New drugs to treat virus expected be available in 2014-15

For more on this rapidly changing landscape, we turned to Dr. Donald M. Jensen, director of the Center for Liver Diseases at University of Chicago Medicine and a noted hepatitis C researcher, with more than 100 peer-reviewed articles.

Published
29 January 2013
From
Chicago Tribune
Phase II all-oral combination studies of simeprevir, TMC647055 and IDX719 for the treatment of hepatitis C to be initiated shortly

The collaboration will evaluate combinations including simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir, TMC647055, a potent once daily NNI (non-nucleoside inhibitor) of the HCV polymerase, boosted with low dose ritonavir, being developed by Janssen and IDX719, Idenix’s once-daily pan-genotypic NS5A inhibitor.

Published
29 January 2013
From
Medivir press release
Guide to Clinical Trials for People with Hepatitis C

There are many new hepatitis C drugs being studied in clinical trials. People with hepatitis C have many options to choose from. Whether you have hepatitis C or another medical condition, deciding to participate in a clinical trial can be complicated. Having more information can help you decide whether or not to participate in a clinical trial, and which trial, or trials, may be right for you.

Published
18 January 2013
From
Treatment Action Group
Achillion Continues To Make Significant Strides In The Fight Against Hepatitis C

Financial analysis of the Achillion hepatitis C drug pipeline; "Achillion is making considerable strides in terms of four drugs currently in its pipeline," Seeking Alpha comments.

Published
15 January 2013
From
Seeking Alpha
Roche Scientists Uncover Unexpected Enzyme Activity in HCV RNA Polymerase

Today, Roche scientists detail the discovery of a new enzyme activity that allows HCV polymerase to remove nucleosides and nucleoside analogues from RNA molecules. This could lead to HCV polymerase counteracting the activity of nucleoside analogs and result in the development of pathways enabling HCV resistance.

Published
11 January 2013
From
Biospace

Filter by country